Literature DB >> 24520856

Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase.

Dana Ferraris1, Bridget Duvall, Greg Delahanty, Bipin Mistry, Jesse Alt, Camilo Rojas, Christopher Rowbottom, Kristen Sanders, Edgar Schuck, Kuan-Chun Huang, Sanjeev Redkar, Barbara B Slusher, Takashi Tsukamoto.   

Abstract

Several 2'-fluorinated tetrahydrouridine derivatives were synthesized as inhibitors of cytidine deaminase (CDA). (4R)-2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydrouridine (7a) showed enhanced acid stability over tetrahydrouridine (THU) 5 at its N-glycosyl bond. As a result, compound 7a showed an improved oral pharmacokinetic profile with a higher and more reproducible plasma exposure in rhesus monkeys compared to 5. Co-administration of 7a with decitabine, a CDA substrate, boosted the plasma levels of decitabine in rhesus monkeys. These results demonstrate that compound 7a can serve as an acid-stable alternative to 5 as a pharmacoenhancer of drugs subject to CDA-mediated metabolism.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24520856     DOI: 10.1021/jm401856k

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

Review 1.  The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?

Authors:  Audrey Frances; Pierre Cordelier
Journal:  Mol Ther       Date:  2019-12-06       Impact factor: 11.454

Review 2.  Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.

Authors:  Anand A Patel; Kirk Cahill; Caner Saygin; Olatoyosi Odenike
Journal:  Blood Adv       Date:  2021-04-27

3.  Synthesis and Pharmacokinetic Evaluation of Siderophore Biosynthesis Inhibitors for Mycobacterium tuberculosis.

Authors:  Kathryn M Nelson; Kishore Viswanathan; Surendra Dawadi; Benjamin P Duckworth; Helena I Boshoff; Clifton E Barry; Courtney C Aldrich
Journal:  J Med Chem       Date:  2015-07-09       Impact factor: 7.446

4.  Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.

Authors:  Guillermo Garcia-Manero; Elizabeth A Griffiths; David P Steensma; Gail J Roboz; Richard Wells; James McCloskey; Olatoyosi Odenike; Amy E DeZern; Karen Yee; Lambert Busque; Casey O'Connell; Laura C Michaelis; Joseph Brandwein; Hagop Kantarjian; Aram Oganesian; Mohammad Azab; Michael R Savona
Journal:  Blood       Date:  2020-08-06       Impact factor: 22.113

5.  Difluoroalkylation of Tertiary Amides and Lactams by an Iridium-Catalyzed Reductive Reformatsky Reaction.

Authors:  Phillip Biallas; Ken Yamazaki; Darren J Dixon
Journal:  Org Lett       Date:  2022-03-08       Impact factor: 6.072

Review 6.  Digging deep into "dirty" drugs - modulation of the methylation machinery.

Authors:  Lisa Pleyer; Richard Greil
Journal:  Drug Metab Rev       Date:  2015-01-08       Impact factor: 4.518

Review 7.  DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge.

Authors:  Omar Castillo-Aguilera; Patrick Depreux; Ludovic Halby; Paola B Arimondo; Laurence Goossens
Journal:  Biomolecules       Date:  2017-01-05

8.  Synthesis and Conformational Analysis of Fluorinated Uridine Analogues Provide Insight into a Neighbouring-Group Participation Mechanism.

Authors:  Freideriki Michailidou; Tomas Lebl; Alexandra M Z Slawin; Sunil Vishnuprasadji Sharma; Murray J B Brown; Rebecca Jane Miriam Goss
Journal:  Molecules       Date:  2020-11-25       Impact factor: 4.411

Review 9.  Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance.

Authors:  Yuriko Saiki; Shuto Hirota; Akira Horii
Journal:  Cancer Drug Resist       Date:  2020-10-12

10.  SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.

Authors:  Nikolas Herold; Sean G Rudd; Kumar Sanjiv; Juliane Kutzner; Julia Bladh; Cynthia B J Paulin; Thomas Helleday; Jan-Inge Henter; Torsten Schaller
Journal:  Cell Cycle       Date:  2017-04-24       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.